Clinical Trial Update: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma and thymoma Type B3 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma Type B3

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: MedSIR | Conditions: Metastatic Thymic Carcinoma, Thymoma Type B3 | Phase 2 | Status: COMPLETED